Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS (ocrelizumab). …
Read MoreLATE BREAKING
all categories
Brief Telehealth Screening of MS Patients in the Medical Setting
Background: A significant clinical need exists for a broad range of health care professionals to be able to objectively screen …
Read More
Connect Trial of Online Professional Support Groups for Black and Latinx People Living with MS
Background: Given the high prevalence of anxiety and depression in MS, many patients struggle to find high quality, professional mental …
Read More
COVID-19 Vaccine Antigenicity in the Setting of MS Disease Modifying Treatments
Background: Although FDA-approved COVID vaccines prevent severe infections in the general population, their efficacy in the face of immune modulation …
Read More
Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab
Background: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of hospitalization, and …
Read More
Early Experience with Cladribine Tablets in an Aging Patient Population
Background: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade in persons with multiple …
Read More
Evaluating the Impact of Administering Ocrelizumab Via a Home Infusion on Safety and Patient Reported Outcomes
Background: US payers are looking to reduce the cost of administering infusible drugs for multiple sclerosis (MS). Home-based infusion has …
Read More
Geographic Variance of MS Prevalence in the United States
Background: The etiology of multiple sclerosis (MS) is not fully understood, and the disease may be triggered or exacerbated by …
Read More
Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab
Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an anti-CD20 …
Read More
Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab
Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts humoral immune response …
Read More
Lowered COVID-19 mRNA Vaccine Antibody Response in MS Patients Treated with B -Cell Depleting and S1P-Receptor-Targeting Therapies Compared to Controls: An Interim Analysis
Background: There are two mRNA vaccines targeting the SARS-CoV2 virus widely used in the U.S. There is limited knowledge about …
Read More
Multiple Sclerosis Diagnosis: Challenges in Telehealth
Background: The COVID-19 pandemic ushered in a new era of telehealth to decrease transmission of the SARS-CoV-2 virus. While this …
Read More
Patient Practices and Experiences during COVID-19 Among Individuals across the United States Enrolled in MS Lifelines Patient Support Program
Background: Research into the impact of COVID-19 on people with MS is ongoing. Objectives: To gain an understanding of COVID-19 …
Read More
Patient-Centered Education and Care Coordination Initiative to Improve Self-Management Skills in Latinos with Multiple Sclerosis
Background: Multiple sclerosis (MS) is a chronic, disabling neurological disease that attacks young adults. Similar to many other chronic conditions …
Read More
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab
Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in adults. …
Read More
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment
Background: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing frequency of approximately …
Read More
Sustained B-Cell Depletion By Inebilizumab Is Associated with Decreased Disease Activity in Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder
Background: Inebilizumab is a humanized, affinity-optimized, anti-CD19 monoclonal antibody approved in Japan, South Korea and the USA to treat neuromyelitis …
Read More
Temporal Trends in Humoral and Cellular Immune Responses to Sars-Cov-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated with Natalizumab, Ocrelizumab or Fumarates
Background: Vaccines against SARS-CoV-2 are a key component of public health measures to combat the COVID-19 pandemic. The impact of …
Read More
The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type
Background: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic, and immunological variables …
Read More
US Real World Experience Switching from Infusion and S1P Therapies to Cladribine Tablets: A Single Center Study
Background: Multiple sclerosis (MS) is a chronic neurological disorder and a major cause of disability in young adults. Cladribine tablets …
Read More
Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)
Background: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more prone to …
Read More